Serum C-reactive protein concentrations in dogs with idiopathic epilepsy

Inflammatory reactions in dogs are associated with systemic changes in serum, called the acute phase response; changes in the concentration of acute phase proteins in the serum take place. C-reactive protein (CRP) is a positive acute phase protein, which increases during inflammation. The role of inflammation in epilepsy remains unclear. In this study, the inflammatory response in dogs with idiopathic epilepsy (1E) was investigated. The aims of the study were: 1. to measure serum CRP concentrations in dogs with IE and in healthy dogs, 2. to measure serum CRP concentrations in dogs with acute cluster seizures and in dogs with isolated seizures and 3. to observe the evolution of serum CRP concentrations in time after the last seizure. This study showed no significant differences in serum CRP concentrations between dogs with IE (7.8 mg/I) and dogs of the control group (8.3 mg/I). Furthermore, the results showed higher mean serum CRP concentrations in dogs with IE exhibiting cluster seizures (11,8 mg/I) than in dogs with isolated seizures (5.7 mg/I). However, these results were not statistically significant (P = 0,077). Finally, no statistically significant decrease in serum CRP concentrations was seen with time after the last epileptic seizure in dogs with IE (P = 0,077)

Primaire idiopatische epilepsie bij de hond: praktische aanpak en een update van de behandeling.

Primaire idiopathische epilepsie is een frequent voorkomende neurologische aandoening bij de hond. De diagnose wordt gesteld door alle andere oorzaken van epilepsie uit te sluiten. Bij een groot deel van de honden kunnen de aanvallen voldoende onder controle gehouden worden met standaardanti-epileptica, zoals fenobarbital en/of kaliumbromide. Voor honden met refractaire epilepsie zijn er een aantal recente humane anti-epileptica voorhanden die kunnen worden toegevoegd aan de standaardbehandeling. De anti-epileptische werking van deze recentere producten bij de hond is gebaseerd op kortetermijnstudies met een klein aantal honden. Uitgebreidere langetermijnstudies zijn nodig vooraleer definitieve besluiten kunnen getrokken worden. Alternatieve behandelingen, zoals nervus vagusstimulatie en de chirurgische verwijdering van de epileptogene focus, zijn mogelijke opties voor de toekomst

Genetic insights in canine degenerative myelopathy

Canine degenerative myelopathy (DM) is a late-onset, progressive, neurodegenerative disorder with a fatal outcome, occurring in a vast number of dog breeds. Most dogs are at least eight years of age when they begin to show clinical signs, starting with general proprioceptive ataxia in the hind limbs and upper motor neuron paraparesis, evolving to lower motor neuron tetraplegia and brain stem signs. A definitive diagnosis can only be made postmortem by the histopathological observation of neuronal degradation and demyelination of the spinal cord. Most DM-affected dogs are homozygous for one of the known superoxide dismutase 1 gene (SOD1) mutations (ENSCAFT00000065394.1:c.82G>A, first described as NM_001003035.1:c.118G>A). A second mutation (NM_001003035.1:c.52A>T) in the same gene has been found but occurs only in Bernese mountain dogs. Not every homozygous dog develops the disease; this indicates that the disease is incompletely penetrant and that modifier loci might be present. In this review, the authors aim to give an overview of the disease progression and the current genetic knowledge of DM, which is of paramount importance for the correct diagnosis and to help reduce the disease incidence

Computed tomographic characteristics of a spinal epidural hemangiosarcoma in a young dog

C

Complicaties na marsupialisatie van een arachnoïd diverticulum bij een rottweiler

A young male Rottweiler had neurological signs since birth. The dog had hypermetria on his front limbs, ataxia on his hind limbs and proprioception was reduced on the hind limbs as well. Computer tomographic examination post myelography and MRI scans showed a long dorsal subarachnoidal diverticulum from cranial C2 up to cranial C5, causing compression of the spinal cord, thus explaining the neurological signs. A cervical dorsal laminectomy was performed, followed by durotomy and marsupialization. Postoperative complications led to revision surgery and on top of that, the patient needed five more days of mechanical ventilation. From then on, the dog was able to breathe on his own and his neurological condition improved step by step. He made a full recovery and eleven months after surgery, he was still doing well

Retrospectieve studie van 20 honden en 1 kat met tetanus (2001-2008)

In 20 dogs and I cat a diagnosis of tetanus was made based on the typical clinical signs and a possible wound history. In 7 animals a tooth abnormality was considered as the entrance way of the bacteria. By means of radiography of the thorax several animals were evaluated for the presence of possible complications such as aspiration pneumonia, megaoesophagus or hiatal hernia. The treatment existed mainly of metronidazole as an antibiotic, acetylpromazine to control the muscle spasms and additional supportive therapy. The survival rate was 71%

Repetitive transcranial magnetic stimulation in drug‐resistant idiopathic epilepsy of dogs : a noninvasive neurostimulation technique

Background Although repetitive transcranial magnetic stimulation (rTMS) has been assessed in epileptic humans, clinical trials in epileptic dogs can provide additional insight. Objectives Evaluate the potential antiepileptic effect of rTMS in dogs. Animals Twelve client-owned dogs with drug-resistant idiopathic epilepsy (IE). Methods Single-blinded randomized sham-controlled clinical trial (dogs allocated to active or sham rTMS) (I) and open-labeled uncontrolled clinical trial (dogs received active rTMS after sham rTMS) (II). Monthly seizure frequency (MSF), monthly seizure day frequency (MSDF), and number of cluster seizures (CS) were evaluated for a 3-month pre-TMS and post-rTMS period and safety was assessed. The lasting effect period of rTMS was assessed in each dog treated by active stimulation using the MSF ratio (proportion of post-TMS to pre-rTMS MSF) and treatment was considered effective if the ratio was No adverse effects were reported. In trial I, MSF and MSDF decreased significantly (P= .04) in the active group (n = 7). In the sham group (n = 5), no significant changes were found (P= .84 and .29, respectively). Cluster seizures did not change significantly in either group. No significant differences were detected between the groups. In trial II, previously sham-treated dogs (n = 5) received active rTMS and significant decreases in MSF and MSDF were noted (P= .03 and .008, respectively). The overall effect of rTMS lasted for 4 months; thereafter, the MSF ratio was >1. Conclusions and Clinical Importance Repetitive transcranial magnetic stimulation may be a safe adjunctive treatment option for dogs with drug-resistant IE, but large-scale studies are needed to establish firm conclusions

Magnetic stimulation of peripheral nerves in dogs: A pilot study

A model for magnetic stimulation of the radial and sciatic nerves in dogs was evaluated. Onset-latencies and peak-to-peak amplitudes of magnetic and electrical stimulation of the sciatic nerve were compared, and the effect of the direction of the current in the magnetic coil on onset-latencies and peak-to-peak amplitude of the magnetic motor evoked potential was studied in both nerves. The results demonstrate that magnetic stimulation is a feasible method for stimulating the radial and sciatic nerves in dogs. No significant differences were observed in onset-latencies and peak-to-peak amplitudes during magnetic and electrical stimulation, indicating conformity between the techniques. Orthodromic or antidromic magnetic nerve Stimulation resulted in no significant differences. This pilot study demonstrates the potential of magnetic stimulation of nerves in dogs